CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Abatacept

Last Updated: August 29, 2008
Result type: Reports
Project Number: S0145
Product Line: Reimbursement Review

Generic Name: Abatacept

Brand Name: Orencia

Manufacturer: Bristol-Myers Squibb Canada

Indications: Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: April 22, 2009

Recommendation Type: List with clinical criteria and/or conditions